CRYOPORT, INC. Deferred Income Tax Assets, Net
CRYOPORT, INC. (CYRX) had Deferred Income Tax Assets, Net of $1.06 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:DeferredIncomeTaxAssetsNet · last filed 2026-08-06
- 2026-06-30: Deferred Income Tax Assets, Net $1.06M.
- 2026-03-31: Deferred Income Tax Assets, Net $1.07M.
- 2025-12-31: Deferred Income Tax Assets, Net $1.07M.
- 2025-09-30: Deferred Income Tax Assets, Net $268.00K.
| Period end | Deferred Income Tax Assets, Net | Deferred Income Tax Assets, Net as first filed |
|---|---|---|
| 2026-06-30 | $1.06M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $1.07M 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $1.07M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $268.00K 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $267.00K 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $614.00K 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $842.00K 10-K · filed 2026-03-05 | $868.00K 10-K · filed 2025-03-07 |
| 2024-09-30 | $1.67M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $1.58M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $758.00K 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $656.00K 10-K · filed 2025-03-07 | |
| 2023-09-30 | $863.00K 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $934.00K 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $937.00K 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $947.00K 10-K · filed 2024-03-13 | |
| 2022-09-30 | $1.64M 10-Q · filed 2022-11-04 | |
| 2022-06-30 | $1.60M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $1.73M 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $419.00K 10-Q · filed 2022-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |